Health Economics›Breast cancer›Metastatic or unresectable disease subsequent lines

Metastatic or unresectable disease subsequent lines

Breast cancer · 30 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 27 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
nab-Paclitaxel, Pertuzumab, Trastuzumab Variant #01	ERBB2	R 138 295	21d	5.3 mo	32.5 mo	6	R 543 283 PFS proxy	2
Paclitaxel, Pertuzumab, Trastuzumab emtansine Variant #01	ERBB2	R 107 315	21d	—	—	~3	~R 215 155 indirect	—
EHP Variant #01	ERBB2	R 103 660	21d	5.3 mo	32.5 mo	3	R 180 757 PFS proxy	2
nab-Paclitaxel and Trastuzumab Variant #01	ERBB2	R 97 652	28d	4.2 mo	25.0 mo	3	R 236 722 PFS proxy	2
GHP Variant #01	ERBB2	R 81 477	21d	5.3 mo	32.5 mo	3	R 114 210 PFS proxy	2
Trastuzumab deruxtecan monotherapy Variant #01	ERBB2	R 81 019	21d	15.5 mo	23.4 mo	2	R 162 039 PFS proxy	9
THP (Docetaxel) Variant #01	ERBB2	R 80 080	21d	5.3 mo	32.5 mo	3	R 110 020 PFS proxy	2
THP (Paclitaxel) Variant #01	ERBB2	R 79 440	21d	5.3 mo	32.5 mo	3	R 108 098 PFS proxy	2
XHP Variant #01	ERBB2	R 79 171	21d	8.2 mo	32.5 mo	3	R 107 293 PFS proxy	3
VHP Variant #01	ERBB2	R 79 048	21d	5.3 mo	32.5 mo	3	R 106 922 PFS proxy	2
Pertuzumab and Trastuzumab Variant #01	ERBB2	R 78 133	21d	—	—	~8	~R 326 050 indirect	—
Capecitabine and Neratinib Variant #01	ERBB2	R 58 797	21d	8.8 mo	—	2	R 117 594 PFS proxy	1
Trastuzumab emtansine monotherapy Variant #01	ERBB2	R 41 405	21d	7.3 mo	29.9 mo	2	R 82 810 PFS proxy	5
Eribulin and Trastuzumab Variant #01	ERBB2	R 39 586	21d	4.9 mo	23.4 mo	3	R 95 325 PFS proxy	5
Vinorelbine and Trastuzumab (VH) Variant #01	ERBB2	R 39 320	28d	5.0 mo	23.4 mo	3	R 61 725 PFS proxy	7
Lapatinib monotherapy Variant #01	ERBB2	R 37 677	28d	1.9 mo	9.5 mo	2	R 75 354 PFS proxy	2
Docetaxel and Trastuzumab (TH) Variant #02	ERBB2	R 31 039	21d	4.2 mo	25.0 mo	4	R 81 980 PFS proxy	2
Eribulin and Margetuximab Variant #01 Partial	ERBB2	R 25 527	21d	6.0 mo	21.6 mo	2	R 51 054 PFS proxy	2
Capecitabine and Lapatinib Variant #01	ERBB2	R 24 587	21d	6.8 mo	21.6 mo	2	R 49 173 PFS proxy	7
Gemcitabine and Trastuzumab Variant #01	ERBB2	R 17 403	21d	4.6 mo	23.4 mo	3	R 28 778 PFS proxy	4
Lapatinib and Trastuzumab Variant #04	ERBB2	R 15 652	42d	2.6 mo	14.0 mo	3	R 32 897 PFS proxy	2
Paclitaxel and Trastuzumab (TH) Variant #01	ERBB2	R 15 366	21d	4.2 mo	25.0 mo	4	R 28 660 PFS proxy	2
Capecitabine and Trastuzumab (XH) Variant #01	ERBB2	R 15 097	21d	5.0 mo	22.7 mo	3	R 21 861 PFS proxy	8
Capecitabine and Trastuzumab (XH) and Tucatinib Variant #01 Partial	ERBB2	R 15 097	21d	7.6 mo	23.3 mo	3	R 21 861 PFS proxy	3
Vinorelbine and Trastuzumab (VH) and Everolimus Variant #01	ERBB2	R 12 125	7d	7.0 mo	—	3	R 22 316 PFS proxy	1
Trastuzumab monotherapy Variant #09	ERBB2	R 9 373	42d	—	—	~2	~R 14 059 PFS proxy · indirect	2
Gemcitabine and Margetuximab Variant #01 Partial	ERBB2	R 3 344	21d	6.0 mo	21.6 mo	2	R 6 688 PFS proxy	2
Capecitabine and Margetuximab Variant #01 Partial	ERBB2	R 1 039	21d	6.0 mo	21.6 mo	2	R 2 077 PFS proxy	2
Capecitabine and Pyrotinib Variant #01 Partial	ERBB2	R 1 039	21d	12.5 mo	—	2	R 2 077 PFS proxy	1
Vinorelbine and Margetuximab Variant #01 Partial	ERBB2	R 915	21d	6.0 mo	21.6 mo	2	R 1 830 PFS proxy	2

30 of 30 regimens shown